Added to YB: 2026-01-05
Pitch date: 2026-01-01
NVO [bullish]
Novo Nordisk A/S
+5.4%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.5T
Pitch Price
DKK 329.00
Price Target
80.00 (-76%)
Dividend
3.53%
EV/EBITDA
9.20
P/E
14.15
EV/Sales
4.87
Sector
Pharmaceuticals
Category
turnaround
Novo Nordisk A/S: All-Out Assault?
NVO: Best obesity pure-play despite 4 guidance cuts in 2025. China/India rollouts targeting 280M patients worth $7B+ revenue at 5% share. Q1 2026 EPS est $1+ vs consensus $0.94-0.98. CagriSema/Amycretin preserve muscle mass vs fat loss, key advantage over Lilly's Zepbound. Target $60-80 vs current price.
Read full article (4 min)